Design Therapeutics Reports Third-Quarter 2026 Results and Business Updates
The company said a registrational plan update for DT-216P2 is anticipated in Q4 2026; the supplied text also mentions 12-week RESTORE-FA data.
Story updates
09:04:00 PM UTC
SquawkNews
Nov 04 (Reuters) - Design Therapeutics Q3 operating income USD -22.23 million.
09:07:32 PM UTC
SquawkNews
Design Therapeutics Q3 Net Loss Widens 19% to $20.29 Million Design Therapeutics’ third-quarter